

**Minutes of the June 10, 2011
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Bill Ladwig, R.Ph.; Debra Farver, PharmD.; James Engelbrecht, M.D.

Members absent

Timothy Soundy, M.D.; Dana Darger, R.Ph.; Willis Sutliff, M.D.; Rick Holm, M.D.

DSS staff present

Mike Jockheck, R.Ph.; Larry Iversen, Director of Medical Services

HID staff present

Candace Rieth, Pharm.D.

Administrative Business

The P&T meeting was called to order by B. Ladwig at approximately 1:00pm. The minutes of the March 4, 2011 meeting were presented. D. Farver made a motion to approve. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for March 2011. There were a total of 2,304 PAs processed in the month of March, with 99.61% of those requests responded to in less than 8 hours. There were 1,283 (95%) requests received electronically and 70 (5%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/01/2011 – 03/31/2011. The top five classes were antipsychotics, cerebral stimulants, amphetamines, adrenals, and antidepressants. The top 15 therapeutic classes make up 41.78% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 17.31% of total claims.

Triptan Review

The P&T committee voted in March to place triptans on prior authorization, grandfathering recipients stable on therapy. C. Rieth presented clinical information, claims data, and a prior authorization form for triptans. M. Gniel, representing Merck, spoke regarding Maxalt. D. Farver made a motion to approve the triptan prior authorization form. J. Engelbrecht seconded the motion. The motion was approved unanimously.

Multiple Sclerosis Agents Review

The P&T committee voted in March to place agents used to treat multiple sclerosis on prior authorization, grandfathering recipients stable on therapy. C. Rieth presented clinical information, data and prior authorization forms for specific agents used to treat multiple sclerosis. C. Jones, representing Acorda, spoke regarding Ampyra. J. Porter and R. Troxell, representing Novartis, spoke regarding Gilenya. The committee addressed each prior authorization form individually. Changes suggested for Ampyra prior authorization form included wording from specialist to physiatrist/neurologist and to remove the timed 25 foot walk requirement. J. Engelbrecht made a motion to approve the form with changes. D. Farver seconded the motion. The motion was approved unanimously. A motion was made by D. Farver to approve the Extavia prior authorization form with criteria including diagnosis and neurologist involved in therapy. J. Engelbrecht seconded the motion. The motion was approved unanimously. Changes suggested for Gilenya prior authorization form included criteria for coverage; neurologist involved in therapy and diagnosis of relapsing multiple sclerosis. D. Farver made a

motion to approve the Gilenya prior authorization form with changes. J. Engelbrecht seconded the motion. The motion was approved unanimously. A motion was made by D. Farver to approve the Novantrone prior authorization form with criteria including diagnosis and neurologist involved in therapy. J. Engelbrecht seconded the motion. The motion was approved unanimously. A motion was made by J. Engelbrecht to approve the Tysabri prior authorization form with criteria including diagnosis, neurologist or gastroenterologist involved in therapy and age of 18 or above. D. Farver seconded the motion. The motion was approved unanimously.

Ophthalmic Antihistamines

The committee placed ophthalmic antihistamines on prior authorization at the March meeting. C. Rieth presented clinical information and data for ophthalmic antihistamines. There was no public comment. A recommendation was made to bring the form back to the September meeting for review.

Less Sedating Antihistamines

The committee asked that less sedating antihistamines be reviewed with recent changes in the class; Allegra gaining OTC status. A recommendation was made to table this topic until the September meeting.

PAH Review

A recommendation was made to table this topic.

Topical Ketoconazole Agents

C. Rieth presented clinical information and claims data for topical ketoconazole agents. There was no public comment. A motion was made by D. Farver to place these agents on prior authorization with a failure of ketoconazole cream or shampoo. J. Engelbrecht seconded the motion. The motion was approved unanimously.

Colcris Review

A recommendation was made to review this topic in the future and include colchicine data.

Horizant Review

C. Rieth presented clinical information for Horizant. B. Streng, representing GSK, spoke regarding Horizant. A recommendation was made to review this topic at the September meeting and include gabapentin, Requip and Mirapex data.

Nexiclon Review

C. Rieth presented clinical information for Nexiclon. There was no public comment. J. Engelbrecht made a motion to place Nexiclon on prior authorization with failure of clonidine as the criteria for coverage. D. Farver seconded the motion. The motion passed unanimously. A prior authorization form will be brought to the September meeting for committee approval.

The next meeting date is scheduled for September 9, 2011. The location will be updated on the website as soon as possible. A motion was made by D. Farver at 2:25pm to adjourn the SD Medicaid P&T meeting. B. Ladwig seconded the motion. Motion passed unanimously and the meeting was adjourned.